Focus: Amicus Therapeutics is a mid-cap biotech specializing in small-molecule treatments for rare lysosomal and genetic diseases, with a commercial footprint anchored by GALAFOLD for Fabry disease. The company operates from Philadelphia with a focused portfolio in rare diseases and cardiovascular indications.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Recent layoff filing — 58 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Amicus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Amicus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Rare disease flagship with 16-year LOE runway; alpha-galactosidase A stabilizer enabling genetic amenability-based dosing for variant Fabry mutations.
Help build intelligence for Amicus Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Phase 3 in growth phase; bis-M6P engineered enzyme replacement with miglustat combination to stabilize GAA in lysosomes, addressing unmet need in acid alpha-glucosidase deficiency.
Glucosylceramide synthase inhibitor at peak lifecycle; approved indication in rare lysosomal storage pathway with 12+ year LOE window.
Post-LOE generic/ANDA formulation with minimal revenue; signals mature lifecycle phase and competitive erosion in storage disease category.
Travere chief makes way for former Amicus CEO—Chutes & Ladders - Fierce Biotech
Travere chief makes way for former Amicus CEO—Chutes & Ladders Fierce Biotech
Travere Therapeutics Announces Planned Chief Executive Officer Transition - Business Wire
Travere Therapeutics Announces Planned Chief Executive Officer Transition Business Wire
8-K Filing: LISATA THERAPEUTICS, INC. (LSTA) (CIK 0000320017) — 8-K
8-K
8-K Filing: Clearway Energy, Inc. (CWEN) (CIK 0001567683) — FORM 8-K
FORM 8-K
8-K Filing: Clearway Energy LLC (CIK 0001637757) — EXHIBIT 99.1
EXHIBIT 99.1
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - MedCity News
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy MedCity News
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Imminent layoff (within 60 days of report date) creates near-term employment instability; roles at Princeton location are high-risk; cross-team knowledge transfer may slow.
Recent peer-reviewed publications with author affiliations at this company
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.
+1 more
+1 more
+1 more
+1 more
+2 more
+1 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo